The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland

Conclusions remained unchanged in most scenarios. Results' drivers included BASDAI50 response rate and disease management cost.CONCLUSION: The bimekizumab treatment-pathway represents a cost-effective option across the axSpA disease spectrum in Scotland. Bimekizumab is cost-effective compared to a secukinumab-pathway that includes dose up-titration, and has similar costs and QALYs to an ixekizumab-pathway.PMID:38650583 | DOI:10.1080/13696998.2024.2342209

Source: Journal of Medical Economics - April 23, 2024 Category: Health Management Authors: Michael F M ørup Vanessa Taieb Damon Willems Micah Rose Nikos Lyris Mark Lamotte Laetitia Gerlier Howard Thom Source Type: research